Pharmalot… Pharmalittle… Good Morning

Hello, folks, and how are you today? Another mild, sunny day is emerging over the Pharmalot corporate campus, where we are hustling to deposit the short people at the schoolhouses and let the mascots out to fertilize the weeds. Too much at once. With all this activity, who needs more stimulation? We do. So please join us as we brew another cup and dig in for a busy day. Here are some interesting items to help you along. Hope your day goes well and drop us a line if you hear something interesting… Compound Pharmacy Restructuring Officer Is ‘Hopelessly Conflicted’ (Reuters) Pfizer Wins EU OK To Expand Prevnar Use To Children (Reuters) China Cuts Prices On 400 Drugs By A 15 Percent Average (Bloomberg News) FDA Reviews Refiled Merck Drug For Use After Surgery (Associated Press) Novartis To Focus On Mid-Sized Deals (Bloomberg News) Bristol-Myers May Sell Experimental Migraine Drug (Bloomberg News) Beta Blockers May Reduce Dementia Risk (CNN) Merck CEO Says Bausch & Lomb Deal Worth Considering (Bloomberg News) Celgene Reports Upbeat Results For Apremilast For Psoriasis (Pharma Times) Novartis And Eisai End COPD Co-Promote Deal (PharmaBiz) Allergan Wants To Sell Obesity Business This Quarter (Bloomberg News) New Packaging Designs May Boost Patient Adherence (Wall Street Journal) Gilead Says It Is On Track With Hepatitis C Treatments (Reuters) Warburg Pincus Buys JHP Pharmaceuticals For $195M (Outsourcing Pharma) Parkinson’s Med May Cause Impulse Control ...
Source: Pharmalot - Category: Pharma Commentators Authors: Tags: Uncategorized Allergan Bausch & Lomb Beta-Blockers Bristol Myers Squibb Celgene Dementia Eisai Gilead Sciences Hepatitis C M&A Merck Migtaine New England Compounding Center Novartis Obesity Parkinson's Pfizer Prescripti Source Type: blogs